Chang P, Quijada UZ, Ramírez R, Calderón PG

Language: Spanish
References: 14
Page: 75-80
PDF size: 332.68 Kb.

ABSTRACT

We present a 66-year-old male who received cetuximab due to recurrence of head and neck cancer of unknown primary, who due to the severity of his cutaneous reaction secondary to cetuximab, was treated with isotretinoin 40 mg daily for one month with good therapeutic results.

REFERENCES

1. Pinto C, Barone CA y Girolomoni G, Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy, Oncologist 2011; 16:228-38.

2. Hassel J, Krippc M et al., Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists, Onkologie 2010; 33:94-8.

3. Hu JC, Sadeghi P, Pinter-Brown LC et al., Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management, J Am Acad Dermatol 2007; 56:317.

4. Vezzoli P, Marzano AV y Onida F, Cetuximab-induced acneiform eruption and the response to isotretinoin, Acta Derm Venereol 2008; 88(1):84-6.

5. Ormaechea N, López A et al., Cetuximab-induced acneiform eruption sparing a previously irradiated skin area, Med Cutan Iber Lat Am 2014; 42(4-6):136-8.

6. Herrera-Acosta E et al., Erupción acneiforme secundaria a cetuximab, Actas Dermosifiliogr 2005; 96(4):252-4.

7. Canosa L et al., Efectos secundarios cutáneos de los fármacos antineoplásicos (ii): inhibidores de cinasas y anticuerpos monoclonales, Piel 2009; 24(8):427-39.

8. Lichtenberger B, Gerber P, Holcmann M et al., Epidermal egfr controls cutaneous host defense and prevents inflammation, Sci Transl Med 2013; 5:199ra111.

9. Eilers R, Gandhi M, Patel J et al., Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy, J Natl Cancer Inst 2010; 102:47.

10. Lynch TJ Jr, Kim ES, Eaby B et al., Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management, Oncologist 2007; 12:610.

11. Chen A, Setser A, Anadkat M et al., Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0, J Am Acad Dermatol 2012; 67:1025.

12. Common Terminology Criteria for Adverse Events (ctcae), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Disponible en: https://ctep.cancer.gov/protocoldevelopment/ electronic_applications/docs/CTCAE_v5_Quick_ Reference_8.5x11.pdf. Consultado: 28 de marzo de 2018.

13. Gerber P et al., Management of egfr-inhibitor associated rash: a retrospective study in 49 patients, European Journal of Medical Research 2012; 17:4.

14. Gutzmer R, Werfel T y Mao R, Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy, Br J Dermatol 2005;153(4):849-51.